Recently, it was proved that GRB7 was stabilized by circCDYL2 through preventing its ubiquitination degradation and enhanced its interaction with FAK, which thus sustained the activities of downstream AKT and ERK1/2 and contributed to trastuzumab resistance in HER2+ breast cancer patients [24]. Here, ERBB2 is linked to breast carcinoma.